Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Cristina Rosa Ferrone

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6295-1085; OpenAlex author ID A5061627885; NIH RePORTER profile ID 9649033. Sources: ClinicalTrials.gov.

Their work

Papers
91 (first author 10, last author 13)
Trials
4 (principal investigator on 2)
Grants
3
Labs led
2
Collaborators
278
Papers, trials and grants by year

2007: 1 trial · 2008: none · 2009: none · 2010: none · 2011: none · 2012: 3 papers · 2013: 4 papers · 2014: 2 papers, 1 grant · 2015: 3 papers · 2016: 4 papers · 2017: 9 papers · 2018: 9 papers · 2019: 7 papers, 1 grant · 2020: 12 papers, 1 trial · 2021: 9 papers, 1 trial, 1 grant · 2022: 7 papers · 2023: 8 papers · 2024: 9 papers · 2025: 2 papers · 2026: 3 papers, 1 trial

Papers 50 of 91

  1. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  2. Lymph Node Yield Is Associated With Improved Overall Survival and Increased Time to Recurrence in Node-Negative Pancreatic Ductal Adenocarcinoma Following Neoa… Co-author DOI 10.1097/sla.0000000000006432↗
  3. Implications of Homologous Recombination Deficiency for Neoadjuvant Platinum-Based Chemotherapy in Pancreatic Cancer: A Narrative Review. Last author DOI 10.1245/s10434-025-19056-0↗
  4. Enhancing management of pancreatic cancer: impact of a same day multidisciplinary clinic on access to guideline-directed care. Co-author DOI 10.1016/j.hpb.2025.07.012↗
  5. Reappraising the Role of Intraoperative Neck Margin Revision in Postneoadjuvant Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Multi-institution… Co-author DOI 10.1097/sla.0000000000006322↗
  6. Accuracy of Clinical Staging in Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jama.2024.16332↗
  7. REDISCOVER the change in surgical management of pancreatic cancer from anatomy to biology. First author DOI 10.1007/s13304-024-01956-7↗
  8. Common hepatic artery lymph node metastasis in pancreatic ductal adenocarcinoma: an analysis of actual survival. Co-author DOI 10.1016/j.gassur.2024.02.018↗
  9. Impact of neoadjuvant chemoradiotherapy on pathologic response in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Co-author DOI 10.1016/j.pan.2024.09.010↗
  10. Tumor Size Reduction and Serum Carbohydrate Antigen 19-9 Kinetics After Neoadjuvant FOLFIRINOX in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.surg.2023.09.041↗
  11. Clinical and pathological factors associated with survival in patients with pancreatic cancer who receive adjuvant therapy after neoadjuvant therapy: A retrosp… Co-author DOI 10.1016/j.surg.2024.01.008↗
  12. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment. Co-author DOI 10.1097/sla.0000000000005874↗
  13. Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006131↗
  14. Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-23-0489↗
  15. Portal Vein or Superior Mesenteric Vein Thrombosis with Dose-Escalated Radiation for Borderline or Locally Advanced Pancreatic Cancer. Co-author DOI 10.1007/s11605-023-05796-5↗
  16. Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer. Co-author DOI 10.1016/j.ejca.2023.113293↗
  17. Surgeon-Led Clinical Trials in Pancreatic Cancer. First author DOI 10.1016/j.soc.2022.08.001↗
  18. Neoadjuvant therapy for pancreatic cancer. First author DOI 10.1038/s41571-023-00746-1↗
  19. Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy. Co-author DOI 10.1093/bjs/znad146↗
  20. Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Receive Neoadjuvant Therapy. Co-author DOI 10.1097/sla.0000000000005354↗
  21. Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis. Co-author DOI 10.1097/xcs.0000000000000499↗
  22. Overexpression of integrin alpha 2 (ITGA2) correlates with poor survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jclinpath-2022-208176↗
  23. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemor… Co-author DOI 10.1007/s00330-021-08304-y↗
  24. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Co-author DOI 10.1016/j.surg.2021.10.015↗
  25. Development and validation of the Massachusetts General Hospital/Memorial Sloan Kettering nomogram to predict overall survival of resected patients with pancre… Co-author DOI 10.1016/j.surg.2022.05.024↗
  26. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Co-author DOI 10.1038/s41588-022-01134-8↗
  27. Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004552↗
  28. Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Last author DOI 10.1097/sla.0000000000004585↗
  29. Prediction of R Status in Resections for Pancreatic Cancer Using Simplified Radiological Criteria. Co-author DOI 10.1097/sla.0000000000005433↗
  30. Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer. Co-author DOI 10.1002/bjs.12003↗
  31. Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. First author DOI 10.1007/s11307-020-01569-7↗
  32. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. Last author DOI 10.1007/s11605-020-04897-9↗
  33. Preoperative cholangitis is an independent risk factor for mortality in patients after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2020.07.025↗
  34. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. Last author DOI 10.1093/jnci/djaa073↗
  35. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.21.01220↗
  36. Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoad… Last author DOI 10.1245/s10434-020-09444-z↗
  37. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  38. Surgery After Response to Chemotherapy for Locally Advanced Pancreatic Ductal Adenocarcinoma: A Guide for Management. First author DOI 10.6004/jnccn.2021.7009↗
  39. Variation in long-term oncologic outcomes by type of cancer center accreditation: An analysis of a SEER-Medicare population with pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2020.03.035↗
  40. Diabetes mellitus is associated with unfavorable pathologic features, increased postoperative mortality, and worse long-term survival in resected pancreatic ca… Co-author DOI 10.1016/j.pan.2019.10.007↗
  41. Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. Co-author DOI 10.1016/j.pan.2020.03.011↗
  42. Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001590↗
  43. Pancreatic Cancer: A Time to Change. Co-author DOI 10.1097/sla.0000000000003910↗
  44. Single-nucleus and spatial transcriptomics of archival pancreatic cancer reveals multi-compartment reprogramming after neoadjuvant treatment Co-author DOI 10.1101/2020.08.25.267336↗
  45. Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes. Co-author DOI 10.1111/his.14067↗
  46. Neoplastic-Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-20-0439↗
  47. Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred? First author DOI 10.1200/jco.19.03318↗
  48. Main Pancreatic Duct to Parenchymal Thickness Ratio at Preoperative Imaging is Associated with Overall Survival in Upfront Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-08040-0↗
  49. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoad… Co-author DOI 10.1245/s10434-019-08084-2↗
  50. Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08354-4↗

Trials 4

  1. Feasibility Study of LUM Imaging System for Pancreatic Cancer Principal investigator NCT04276909↗
  2. International Pancreatic Surgery Outcomes Study - PancreasGroup.Org Study chair NCT04652271↗
  3. Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer Study chair NCT04340141↗
  4. Management of Incidentally Discovered Pancreatic Cysts Principal investigator NCT00550108↗

Grants 3

  1. B7-H3 CAR T cell-based immunotherapy combined with Losartan to counteract desmoplasia for the treatment of Pancreatic Ductal Adenocarcinoma (PDAC) R03CA249542↗
  2. IL-15 TRiKES-based specific immunotherapy of pancreatic ductal adenocarcinoma R03CA231766↗
  3. Grp94 targeted therapy for pancreatic ductal adenocarcinoma R21CA164756↗

Closest collaborators

The 25 strongest of 278 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keith D. Lillemoe · 58 shared papers, 2012–2026 · strength 5.93
  2. Motaz Qadan · 33 shared papers, 2018–2026 · strength 4.40
  3. Carlos F. Fernandez-del Castillo · 44 shared papers, 2012–2024 · strength 4.21
  4. Theodore Sunki Hong · 34 shared papers, 2013–2024 · strength 3.07
  5. Jennifer Yon-Li Wo · 25 shared papers, 2013–2024 · strength 2.25
  6. David P. Ryan · 25 shared papers, 2013–2024 · strength 2.21
  7. Andrew Louis Warshaw · 25 shared papers, 2012–2024 · strength 2.10
  8. Carlos Fernández-del Castillo · 18 shared papers, 2013–2026 · strength 1.99
  9. Lawrence Scott Blaszkowsky · 19 shared papers, 2013–2024 · strength 1.64
  10. Zhi Ven Fong · 10 shared papers, 2017–2026 · strength 1.58
  11. Soldano Ferrone · 4 shared papers, 3 shared grants, 2014–2021 · strength 1.44
  12. Marco Ventin · 4 shared papers, 2024–2026 · strength 1.21
  13. Colin D. Weekes · 10 shared papers, 2017–2024 · strength 1.09
  14. Vikram Deshpande · 13 shared papers, 2012–2023 · strength 1.04
  15. Thomas P. Hank · 8 shared papers, 2020–2024 · strength 0.98
  16. Theodoros P. Michelakos · 11 shared papers, 2016–2022 · strength 0.96
  17. Aparna R. Parikh · 8 shared papers, 2018–2024 · strength 0.95
  18. Akhil Chawla · 5 shared papers, 2019–2023 · strength 0.95
  19. David Tsai Ting · 10 shared papers, 2015–2024 · strength 0.86
  20. Mari A. Mino-Kenudson · 10 shared papers, 2012–2024 · strength 0.80
  21. Arsen Osipov · 3 shared papers, 2024–2026 · strength 0.76
  22. Louisa Bolm · 4 shared papers, 2022–2026 · strength 0.74
  23. Jon Michael Harrison · 5 shared papers, 2020–2024 · strength 0.70
  24. Maximiliano Servín-Rojas · 3 shared papers, 2024–2026 · strength 0.67
  25. Giuseppe Malleo · 5 shared papers, 2017–2025 · strength 0.64

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.